226 related articles for article (PubMed ID: 30452422)
1. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy.
Finanger E; Vandenborne K; Finkel RS; Lee Sweeney H; Tennekoon G; Yum S; Mancini M; Bista P; Nichols A; Liu H; Fretzen A; Donovan JM
J Neuromuscul Dis; 2019; 6(1):43-54. PubMed ID: 30452422
[TBL] [Abstract][Full Text] [Related]
2. A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.
Donovan JM; Zimmer M; Offman E; Grant T; Jirousek M
J Clin Pharmacol; 2017 May; 57(5):627-639. PubMed ID: 28074489
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial.
Finkel RS; Finanger E; Vandenborne K; Sweeney HL; Tennekoon G; Shieh PB; Willcocks R; Walter G; Rooney WD; Forbes SC; Triplett WT; Yum SW; Mancini M; MacDougall J; Fretzen A; Bista P; Nichols A; Donovan JM
Neuromuscul Disord; 2021 May; 31(5):385-396. PubMed ID: 33678513
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial.
Finkel RS; McDonald CM; Lee Sweeney H; Finanger E; Neil Knierbein E; Wagner KR; Mathews KD; Marks W; Statland J; Nance J; McMillan HJ; McCullagh G; Tian C; Ryan MM; O'Rourke D; Müller-Felber W; Tulinius M; Burnette WB; Nguyen CT; Vijayakumar K; Johannsen J; Phan HC; Eagle M; MacDougall J; Mancini M; Donovan JM;
J Neuromuscul Dis; 2021; 8(5):769-784. PubMed ID: 34120912
[TBL] [Abstract][Full Text] [Related]
5. Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to swallow softgel capsules: Clinical trial experience with edasalonexent.
Mancini M; Shafai G; Thaler E; Donovan JM; Finkel RS
J Clin Pharm Ther; 2022 Jan; 47(1):33-37. PubMed ID: 34263472
[TBL] [Abstract][Full Text] [Related]
6. Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.
Previtali SC; Gidaro T; Díaz-Manera J; Zambon A; Carnesecchi S; Roux-Lombard P; Spitali P; Signorelli M; Szigyarto CA; Johansson C; Gray J; Labolle D; Porte Thomé F; Pitchforth J; Domingos J; Muntoni F
Pharmacol Res; 2020 Sep; 159():104999. PubMed ID: 32535224
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy.
Ricotti V; Spinty S; Roper H; Hughes I; Tejura B; Robinson N; Layton G; Davies K; Muntoni F; Tinsley J
PLoS One; 2016; 11(4):e0152840. PubMed ID: 27055247
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet.
Muntoni F; Tejura B; Spinty S; Roper H; Hughes I; Layton G; Davies KE; Harriman S; Tinsley J
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):922-933. PubMed ID: 30650257
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy.
Wagner KR; Abdel-Hamid HZ; Mah JK; Campbell C; Guglieri M; Muntoni F; Takeshima Y; McDonald CM; Kostera-Pruszczyk A; Karachunski P; Butterfield RJ; Mercuri E; Fiorillo C; Bertini ES; Tian C; Statland J; Sadosky AB; Purohit VS; Sherlock SP; Palmer JP; Binks M; Charnas L; Marraffino S; Wong BL
Neuromuscul Disord; 2020 Jun; 30(6):492-502. PubMed ID: 32522498
[TBL] [Abstract][Full Text] [Related]
10. Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study.
Hafner P; Bonati U; Erne B; Schmid M; Rubino D; Pohlman U; Peters T; Rutz E; Frank S; Neuhaus C; Deuster S; Gloor M; Bieri O; Fischmann A; Sinnreich M; Gueven N; Fischer D
PLoS One; 2016; 11(1):e0147634. PubMed ID: 26799743
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying effects of orally bioavailable NF-
Hammers DW; Sleeper MM; Forbes SC; Coker CC; Jirousek MR; Zimmer M; Walter GA; Sweeney HL
JCI Insight; 2016 Dec; 1(21):e90341. PubMed ID: 28018975
[TBL] [Abstract][Full Text] [Related]
12. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
Campbell C; McMillan HJ; Mah JK; Tarnopolsky M; Selby K; McClure T; Wilson DM; Sherman ML; Escolar D; Attie KM
Muscle Nerve; 2017 Apr; 55(4):458-464. PubMed ID: 27462804
[TBL] [Abstract][Full Text] [Related]
13. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR
Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580
[TBL] [Abstract][Full Text] [Related]
14. Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy.
Zimmerman A; Clemens PR; Tesi-Rocha C; Connolly A; Iannaccone ST; Kuntz N; Arrieta A; Hache L; Henricson E; Hu F; Mayhew J; Escolar DM
Muscle Nerve; 2011 Aug; 44(2):170-3. PubMed ID: 21674534
[TBL] [Abstract][Full Text] [Related]
15. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy.
Monici MC; Aguennouz M; Mazzeo A; Messina C; Vita G
Neurology; 2003 Mar; 60(6):993-7. PubMed ID: 12654966
[TBL] [Abstract][Full Text] [Related]
16. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
Hoffman EP; Schwartz BD; Mengle-Gaw LJ; Smith EC; Castro D; Mah JK; McDonald CM; Kuntz NL; Finkel RS; Guglieri M; Bushby K; Tulinius M; Nevo Y; Ryan MM; Webster R; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Siener C; Jaros M; Shale P; McCall JM; Nagaraju K; van den Anker J; Conklin LS; Cnaan A; Gordish-Dressman H; Damsker JM; Clemens PR;
Neurology; 2019 Sep; 93(13):e1312-e1323. PubMed ID: 31451516
[TBL] [Abstract][Full Text] [Related]
17. Systemic administration of PRO051 in Duchenne's muscular dystrophy.
Goemans NM; Tulinius M; van den Akker JT; Burm BE; Ekhart PF; Heuvelmans N; Holling T; Janson AA; Platenburg GJ; Sipkens JA; Sitsen JM; Aartsma-Rus A; van Ommen GJ; Buyse G; Darin N; Verschuuren JJ; Campion GV; de Kimpe SJ; van Deutekom JC
N Engl J Med; 2011 Apr; 364(16):1513-22. PubMed ID: 21428760
[TBL] [Abstract][Full Text] [Related]
18. Vibration therapy tolerated in children with Duchenne muscular dystrophy: a pilot study.
Myers KA; Ramage B; Khan A; Mah JK
Pediatr Neurol; 2014 Jul; 51(1):126-9. PubMed ID: 24830767
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.
Buyse GM; Voit T; Schara U; Straathof CSM; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; McDonald CM; Rummey C; Meier T;
Lancet; 2015 May; 385(9979):1748-1757. PubMed ID: 25907158
[TBL] [Abstract][Full Text] [Related]
20. Reliability and validity of the Thai version of the Pediatric Quality of Life inventory™ 3.0 Duchenne Muscular Dystrophy module in Thai children with Duchenne Muscular Dystrophy.
Thongsing A; Likasitwattanakul S; Sanmaneechai O
Health Qual Life Outcomes; 2019 May; 17(1):76. PubMed ID: 31046775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
